People taking glucagon-like peptide-1 (GLP-1) receptor agonists reported nail detachment and discoloration more often than nonusers with obesity or type 2 diabetes in a multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. The cross-sectional analysis compared 575 GLP-1 users with 1,329 nonusers across four countries, but it cannot establish that the medications caused the nail changes.
Nail detachment and discoloration were more common among GLP-1 users
The findings were reported at EADV Congress 2026 in Vienna, held from September 30 to October 3. Researchers recruited participants in France, the United States, Brazil, and Mexico. They compared people taking GLP-1 receptor agonists with people who had obesity, type 2 diabetes, or both but had never used the drugs. Of the 1,904 participants, 575 were users and 1,329 were controls.
At least one nail disorder was reported by 66% of GLP-1 users and 53% of controls. Nail detachment was reported by 39% versus 9%, while nail discoloration was reported by 46% versus 17%, respectively. These are proportions reporting symptoms, not prospectively measured rates of newly diagnosed nail disease. The large difference for nail detachment, approximately 4.3-fold before adjustment, does not mean an individual starting treatment faces a 39% risk of developing the condition.
The investigators reported that the differences persisted in an analysis limited to people who lost weight. After statistical adjustment for dermatological conditions and nutritional deficiencies, the associations weakened, although detachment and discoloration remained about two to three times more common among users. The EADV release did not provide complete adjusted estimates, confidence intervals, or a detailed model specification, so those analyses should not be interpreted more precisely than the available report allows.
Nail detachment means the nail plate separates from its underlying bed
Nail detachment, called onycholysis, occurs when part of the nail plate separates from the nail bed. The separated portion may look white, opaque, or discolored because air occupies the space beneath it. It can affect fingernails or toenails and may create an opening where moisture and organisms accumulate. Nail discoloration is a broader observation, not a single diagnosis.
These signs have many possible explanations. Trauma from manicures, repeated pressure, fungal infection, inflammatory skin conditions, and other medical problems can cause nail changes. A patient-reported survey cannot reliably sort these causes without standardized examinations or confirmatory testing. The congress report does not show that every participant who reported detachment had dermatologist-confirmed onycholysis.
Weight loss and reduced dietary intake may contribute, but the mechanism remains unresolved
GLP-1 receptor agonists are used to treat type 2 diabetes and obesity. The medicines influence appetite and glucose regulation, as outlined in our explainer on how GLP-1 works in the body. Some patients eat substantially less during treatment. Inadequate nutritional intake can affect tissues that require continuous protein synthesis, including hair and nails, but the present study did not establish a biochemical pathway connecting GLP-1 receptor activation to nail detachment.
The finding that differences persisted among participants who had lost weight is informative but not definitive. A comparison of people who lost weight does not eliminate differences in the speed of weight loss, food intake, preexisting health conditions, medication use, or exposure to nail trauma. Statistical adjustment can reduce measured confounding, not remove every unmeasured explanation.
Reports of hair loss among GLP-1 users have prompted similar questions about drug effects versus consequences of weight reduction. A companion EADV analysis involving these same participants found greater self-reported unusual shedding and hair-volume loss among users. Because the studies share participants and a cross-sectional design, the hair findings do not independently establish a nail-related biological mechanism.
Preexisting symptoms make a direct drug effect difficult to isolate
Approximately half of the GLP-1 users said they had experienced nail problems before starting treatment. That detail changes how the headline percentages should be read. The comparison describes symptoms reported in two groups at a point in time; it does not distinguish all longstanding problems from those that started during therapy.
Researchers also lacked the benefit of examining everyone before their first dose and following them at defined intervals. Without that chronology, the analysis cannot calculate an incidence rate attributable to medication, determine whether symptoms resolve after exposure ends, or establish a dose-response relationship. It also cannot reliably separate semaglutide from tirzepatide or other medicines unless drug-specific data are presented. Our comparison of GLP-1 pills and injections describes how formulations differ, but this nail survey cannot show that any particular formulation is responsible.
Study author Charles Taïeb captured the central limitation in the EADV release: “not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.” That distinction matters when symptoms are common in the underlying patient population.
What the evidence cannot yet answer
The findings were presented at a scientific congress and described in an EADV press release. A complete peer-reviewed paper containing the underlying questionnaire, sampling methods, drug-specific breakdown, effect estimates, and prespecified statistical analyses was not available in the material verified for this report. The conference citation should not be represented as a journal article with a DOI.
Both the nail and companion scalp studies were cross-sectional and relied on self-reported symptoms. Selection and recall bias may affect how patients described nail problems, and other factors may differ between exposed and unexposed participants. The available report does not establish when nail changes began, how long they persisted, which changes were clinically confirmed, or whether GLP-1 treatment directly altered nail biology.
The study received institutional support from DUCRAY Laboratories, part of the Pierre Fabre Group, which develops dermatological and hair-care products. That funding context is relevant when interpreting preliminary findings. The EADV report did not provide a complete individual author conflict-of-interest table.
New nail changes warrant assessment, not automatic treatment discontinuation
Someone who notices a nail lifting, persistent discoloration, pain, swelling, or signs of infection should seek medical assessment. A clinician can review nail trauma, dermatologic conditions, medications, and possible nutritional concerns rather than assuming the GLP-1 medicine is responsible. Patients should not independently stop prescribed treatment on the basis of this observational association.
In the EADV release, study author Bruno Halioua advised patients to discuss nail, scalp, and hair symptoms with their doctor rather than discontinue therapy on their own. The research team plans prospective studies with standardized skin and nail examinations and biological monitoring. Such studies are needed to learn whether these changes develop more often after treatment starts, whether a reproducible mechanism exists, and whether they reverse.
References
- Piraccini BM, Mengeaud V, Ribet V, et al. Association between GLP-1 receptor agonists and nail disorders: Results from a multinational case-control study. Presented at EADV Congress 2026, Vienna, Austria, September 30–October 3, 2026. EADV conference release. No journal DOI reported.
- Halioua B, Taïeb C, Couttet A, et al. Association between GLP-1 receptor agonists and scalp involvement: Results from a multinational case-control study. Presented at EADV Congress 2026, Vienna, Austria, September 30–October 3, 2026. EADV conference release. No journal DOI reported.